DOVA stock climbed Monday after Dova Pharmaceuticals (NASDAQ:DOVA) announced a buyout offer from a Swedish drugmaker, Orphan Biovitrum.
Here’s everything we know about the deal, from start to finish.DOVA Stock Goes Flying on Buyout News
On September 30, Dova Pharmaceuticals said Swedish Orphan Biovitrum will purchase the company for $27.50 a share in cash. If, however, the FDA approves Dova’s primary candidate Doptelet, which is used in the treatment of chemotherapy-induced thrombocytopenia, Orphan Biovitrum (OM: SOBI) will buy the company for an additional $1.50 a share.
“We are extremely pleased to ...